Welcome to our dedicated page for Pds Biotechnology Corporation SEC filings (Ticker: PDSB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PDS Biotechnology Corporation filings document the formal disclosures of a late-stage biotechnology company developing targeted immunotherapies for cancer. Recent 8-K reports furnish operating and financial results, business updates, corporate presentations, and press-release exhibits covering PDS0101, VERSATILE-003, PDS01ADC, and related clinical and biomarker data.
The filing record also includes material-event disclosures on FDA and IND protocol matters, Nasdaq listing-compliance correspondence, exhibit filings, capital-structure topics, shareholder voting matters, and the risk and forward-looking-statement language attached to the company’s clinical-development and financing activities.
PDS Biotechnology Corporation (NASDAQ: PDSB) filed a Form 8-K on June 25, 2025 under Item 8.01 to announce that it has updated its corporate presentation deck. The new June 2025 slide deck is furnished as Exhibit 99.1 and incorporated by reference into the filing. No financial statements, earnings figures, strategic transactions, or other material events were disclosed. Investors should review the furnished deck for any updated development timelines or clinical program highlights; however, the 8-K itself contains no additional quantitative or qualitative information.